TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from AIM ImmunoTech ( (AIM) ) is now available.
AIM ImmunoTech announced its participation in the Maxim Growth Summit 2025 in New York, where it will present its ongoing and future activities related to Ampligen®. The company is conducting significant testing and trials to assess Ampligen®’s effectiveness, but faces uncertainties such as regulatory approvals and trial outcomes, which could impact its operations and market positioning.
The most recent analyst rating on (AIM) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on AIM ImmunoTech stock, see the AIM Stock Forecast page.
Spark’s Take on AIM Stock
According to Spark, TipRanks’ AI Analyst, AIM is a Underperform.
AIM ImmunoTech’s overall stock score is primarily impacted by its poor financial performance and bearish technical indicators. The company’s negative profitability, weak balance sheet, and noncompliance with NYSE requirements are significant risks. While recent positive study results and a public offering are potential positives, they do not outweigh the financial and technical challenges.
To see Spark’s full report on AIM stock, click here.
More about AIM ImmunoTech
AIM ImmunoTech operates in the biotechnology industry, focusing on the development of therapeutics for viral diseases, cancers, and immune-deficiency disorders. Their primary product under investigation is Ampligen®, which is undergoing various stages of testing and trials to determine its efficacy in treating these conditions.
Average Trading Volume: 213,831
Technical Sentiment Signal: Sell
Current Market Cap: $6.96M
See more insights into AIM stock on TipRanks’ Stock Analysis page.